These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Acute injury with intravenous iron and concerns regarding long-term safety. Bishu K; Agarwal R Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372 [TBL] [Abstract][Full Text] [Related]
23. Uncommon adverse effect of a common medication. Moore KL; Kildahl-Andersen O; Kildahl-Andersen R; Tjønnfjord GE Tidsskr Nor Laegeforen; 2013 Jan; 133(2):165. PubMed ID: 23344600 [No Abstract] [Full Text] [Related]
24. A randomized trial of intravenous and oral iron in chronic kidney disease. Agarwal R; Kusek JW; Pappas MK Kidney Int; 2015 Oct; 88(4):905-14. PubMed ID: 26083656 [TBL] [Abstract][Full Text] [Related]
25. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate. Sane R; Baribeault D; Rosenberg CL Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390 [TBL] [Abstract][Full Text] [Related]
26. Intravenous iron in the treatment of anemia of pregnancy. 1949. Govan AD; Scott JM Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123 Suppl 2():S33-5. PubMed ID: 16360540 [No Abstract] [Full Text] [Related]
27. Anemia during pregnancy and in the postpartum: intravenous iron therapy revisited. Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123 Suppl 2():S1-35. PubMed ID: 16360535 [No Abstract] [Full Text] [Related]
29. Iron hydroxide polymaltose: iatrogenic cause of persistent iron deficiency anaemia despite continuous oral iron therapy. Mehta BC J Assoc Physicians India; 2002 Feb; 50():279-80. PubMed ID: 12038667 [No Abstract] [Full Text] [Related]
30. Iron Sucrose and Blood Pressure Patterns During Hemodialysis. Yan J; Winkelmayer WC; Walther CP Am J Kidney Dis; 2023 Jun; 81(6):629-631. PubMed ID: 37012095 [No Abstract] [Full Text] [Related]
31. Intravenous Iron Sucrose Therapy in Iron Deficiency Anemia in Antenatal and Postnatal Patients. Sharma J; Tiwari S JNMA J Nepal Med Assoc; 2015; 53(198):104-7. PubMed ID: 26994029 [TBL] [Abstract][Full Text] [Related]
32. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease]. Potthoff SA; Münch HG Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117 [TBL] [Abstract][Full Text] [Related]
33. Clinical update: intravenous iron for anaemia. Auerbach M; Ballard H; Glaspy J Lancet; 2007 May; 369(9572):1502-1504. PubMed ID: 17482969 [No Abstract] [Full Text] [Related]
34. The safety of intravenous iron sucrose use in the elderly patient. Reed J; Charytan C; Yee J Consult Pharm; 2007 Mar; 22(3):230-8. PubMed ID: 17658969 [TBL] [Abstract][Full Text] [Related]
35. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease. Kowalczyk M; Banach M; Rysz J J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770 [TBL] [Abstract][Full Text] [Related]
36. Treatment of childhood-onset restless legs syndrome and periodic limb movement disorder using intravenous iron sucrose. Grim K; Lee B; Sung AY; Kotagal S Sleep Med; 2013 Nov; 14(11):1100-4. PubMed ID: 23993871 [TBL] [Abstract][Full Text] [Related]
37. Risk of Anaphylaxis With Intravenous Iron Products. Wang C; Wong S; Graham DJ JAMA; 2016 May 24-31; 315(20):2232-3. PubMed ID: 27218636 [No Abstract] [Full Text] [Related]
38. Risk of Anaphylaxis With Intravenous Iron Products. DeLoughery TG JAMA; 2016 May 24-31; 315(20):2232. PubMed ID: 27218635 [No Abstract] [Full Text] [Related]
39. [Iron protein-succinylate in the treatment of adult iron-deficiency anemia]. Pujol Farriols R; Anglada Oriol M; Formiga Pérez F; Fernández-Sabe N; Mitjavila Vileró F; Vidaller Palacín A An Med Interna; 2002 Dec; 19(12):651-2. PubMed ID: 12593038 [No Abstract] [Full Text] [Related]